Humanized immune system mouse models with functional human NK cells are critical for evaluation of antibody-based therapeutics, but existing models have only a low frequency of human NK cells. Two novel transgenic mouse models, hIL-2 NOG and hIL-15 NOG, have recently been developed to study NK cell biology as well as evaluate NK cell-mediated in vivo cytotoxicity.

Validating Antibody Drug Targets in hIL-2 NOG and hIL-15 NOG Mice

In this exclusive webinar, join Dr. Takeshi Takahashi of the CIEA as he examines the performance and applications of humanized hIL-2 NOG and hIL-15 NOG mice in immuno-oncology drug discovery.

Watch this webinar to:

• Learn how NK cells are engrafted to create translatable human immune system models
  
  
• Share data on NK cell development and performance in immuno-oncology studies
  
  
• Discover how the hIL-2 NOG and hIL-15 NOG mice accelerate research into antibody-based therapeutics

Presenter

Dr. Takeshi Takahashi is head of the Immunology Lab at the Central Institute for Experimental Animals (CIEA) in Kawasaki, Japan. He completed his PhD at Osaka University and spent seven years studying regulatory T cells at Kyoto University with Prof. Sakaguchi.

After working with Stanford University and DRFZ as a visiting scientist, Dr. Takeshi Takahashi began researching humanized mice at Tohoku University and joined the CIEA in 2011. He has published thirty peer-reviewed papers in the field of immunology.

Watch Now!